KR101759499B1
(ko)
|
2009-07-31 |
2017-07-19 |
사노피-아벤티스 도이칠란트 게엠베하 |
지속형 인슐린 조성물
|
EP2459228B1
(en)
|
2009-07-31 |
2020-03-04 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an insulin linker conjugate
|
WO2011051406A1
(en)
|
2009-10-29 |
2011-05-05 |
Ascendis Pharma As |
Sterilization of biodegradable hydrogels
|
HUE038405T2
(hu)
|
2009-12-15 |
2018-10-29 |
Ascendis Pharma Endocrinology Div A/S |
Átmenetileg polimer hordozóhoz kapcsolt száraz növekedési hormon készítmény
|
EP2525831B1
(en)
|
2010-01-22 |
2019-05-15 |
Ascendis Pharma A/S |
Carrier-linked carbamate prodrug linkers
|
EP2525830B1
(en)
|
2010-01-22 |
2016-05-11 |
Ascendis Pharma A/S |
Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
|
EP2525829A1
(en)
|
2010-01-22 |
2012-11-28 |
Ascendis Pharma A/S |
Dipeptide-based prodrug linkers for aromatic amine-containing drugs
|
US9517257B2
(en)
|
2010-08-10 |
2016-12-13 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
US9850296B2
(en)
|
2010-08-10 |
2017-12-26 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
JP6017422B2
(ja)
|
2010-08-10 |
2016-11-02 |
エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) |
赤血球結合療法
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
US10451897B2
(en)
|
2011-03-18 |
2019-10-22 |
Johnson & Johnson Vision Care, Inc. |
Components with multiple energization elements for biomedical devices
|
EP2704695A1
(en)
*
|
2011-05-03 |
2014-03-12 |
Telik, Inc. |
Excipient compatibility with ezatiostat
|
EP3597206A1
(en)
*
|
2011-06-21 |
2020-01-22 |
BVW Holding AG |
Medical device comprising boswellic acid
|
WO2013024051A1
(en)
*
|
2011-08-12 |
2013-02-21 |
Ascendis Pharma A/S |
Sustained release composition of prostacyclin
|
AU2012296955B2
(en)
|
2011-08-12 |
2016-12-15 |
Ascendis Pharma A/S |
Carrier-linked prodrugs having reversible carboxylic ester linkages
|
IN2014CN00989A
(hu)
*
|
2011-08-12 |
2015-04-10 |
Ascendis Pharma As |
|
MX2014003993A
(es)
*
|
2011-10-12 |
2014-08-08 |
Ascendis Pharma Ophthalmology Division As |
Prevencion y tratamiento de condiciones oculares.
|
AU2012331279A1
(en)
*
|
2011-11-03 |
2014-05-08 |
Bayer Intellectual Property Gmbh |
Tyrosine based linkers for the releasable connection of peptides
|
US8857983B2
(en)
|
2012-01-26 |
2014-10-14 |
Johnson & Johnson Vision Care, Inc. |
Ophthalmic lens assembly having an integrated antenna structure
|
AU2013254756B2
(en)
|
2012-04-25 |
2017-03-30 |
Ascendis Pharma A/S |
Prodrugs of hydroxyl-comprising drugs
|
WO2014002039A1
(en)
*
|
2012-06-27 |
2014-01-03 |
Shire Ag |
Amphetamine prodrugs
|
CA2882490A1
(en)
|
2012-08-21 |
2014-02-27 |
Ortho-Clinical Diagnostics, Inc. |
Antibodies to paliperidone and use thereof
|
CN104822660A
(zh)
|
2012-08-21 |
2015-08-05 |
詹森药业有限公司 |
阿立哌唑半抗原及其在免疫测定中的应用
|
CN104736565B
(zh)
|
2012-08-21 |
2019-03-12 |
詹森药业有限公司 |
利培酮半抗原的抗体及其用途
|
EP3933406A3
(en)
|
2012-08-21 |
2022-04-20 |
Janssen Pharmaceutica NV |
Antibodies to risperidone and use thereof
|
JP6286429B2
(ja)
*
|
2012-08-21 |
2018-02-28 |
ヤンセン ファーマシューティカ エヌ.ベー. |
パリペリドンのハプテン
|
EP3663316A1
(en)
|
2012-08-21 |
2020-06-10 |
Janssen Pharmaceutica NV |
Antibodies to aripiprazole and use thereof
|
CN110054694B
(zh)
|
2012-08-21 |
2024-02-20 |
詹森药业有限公司 |
阿立哌唑半抗原的抗体及其用途
|
AU2013305938B2
(en)
|
2012-08-21 |
2017-08-17 |
Saladax Biomedical Inc. |
Antibodies to paliperidone haptens and use thereof
|
AU2013328774B2
(en)
|
2012-10-11 |
2017-11-30 |
Ascendis Pharma A/S |
Diagnosis, prevention and treatment of diseases of the joint
|
SG11201501914XA
(en)
*
|
2012-10-11 |
2015-05-28 |
Ascendis Pharma Ophthalmology Division As |
Vegf neutralizing prodrugs for the treatment of ocular conditions
|
RU2647729C2
(ru)
|
2012-10-11 |
2018-03-19 |
Асцендис Фарма Ас |
Пролекарства на основе гидрогеля
|
US9913912B2
(en)
|
2012-12-07 |
2018-03-13 |
Ascendis Pharma A/S |
Carrier-linked prostanoid prodrugs
|
US20140271885A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Intezyne Technologies, Inc. |
Copolymers for stable micelle formulations
|
CA2907830C
(en)
*
|
2013-04-22 |
2022-03-29 |
Ascendis Pharma A/S |
Hydrogel-linked prodrugs releasing tagged drugs
|
JP6311008B2
(ja)
*
|
2013-04-22 |
2018-04-11 |
アセンディス ファーマ エー/エス |
修飾されたヒドロゲル
|
WO2014205126A1
(en)
|
2013-06-19 |
2014-12-24 |
The Regents Of The University Of California |
Chemical structures for localized delivery of therapeutic agents
|
RU2543375C1
(ru)
*
|
2013-07-29 |
2015-02-27 |
Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный университет" |
Комплексное соединение производного метилурацила с органической кислотой и способ его получения
|
JP6539274B2
(ja)
|
2013-08-12 |
2019-07-03 |
ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド |
押出成形された即放性乱用抑止性丸剤
|
RU2016117052A
(ru)
|
2013-10-01 |
2017-11-10 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Соединения для аффинной хроматографии и для продления времени полужизни терапевтического средства
|
AU2014333953C1
(en)
*
|
2013-10-08 |
2020-06-25 |
Ascendis Pharma A/S |
Hydrogel-linked IL-1ra prodrug
|
CN103554296B
(zh)
*
|
2013-10-12 |
2015-09-16 |
天津大学 |
一种亚油酸改性葡聚糖及制备高分子脂质体的方法
|
CA2929201A1
(en)
|
2013-11-11 |
2015-05-14 |
Ascendis Pharma Relaxin Division A/S |
Relaxin prodrugs
|
US9675607B2
(en)
*
|
2013-11-13 |
2017-06-13 |
Northwestern University |
Epimorphic regeneration and related hydrogel delivery systems
|
WO2015095391A1
(en)
|
2013-12-17 |
2015-06-25 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
CN103706233A
(zh)
*
|
2013-12-17 |
2014-04-09 |
杨亮月 |
一种环氧乙烷零排放处理体系及方法
|
US9492444B2
(en)
|
2013-12-17 |
2016-11-15 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
JP6744227B2
(ja)
|
2014-02-21 |
2020-08-19 |
エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) |
糖標的化治療剤
|
US10046056B2
(en)
|
2014-02-21 |
2018-08-14 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
US10946079B2
(en)
|
2014-02-21 |
2021-03-16 |
Ecole Polytechnique Federale De Lausanne |
Glycotargeting therapeutics
|
US10953101B2
(en)
|
2014-02-21 |
2021-03-23 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
JP6625550B2
(ja)
|
2014-03-14 |
2019-12-25 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Tco複合体および治療薬の送達のための方法
|
JP6371463B2
(ja)
|
2014-07-17 |
2018-08-08 |
ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド |
即時放出性乱用抑止性液体充填剤形
|
WO2016011387A1
(en)
|
2014-07-17 |
2016-01-21 |
The Regents Of The University Of California |
Controllable self-annealing microgel particles for biomedical applications
|
WO2016020373A1
(en)
|
2014-08-06 |
2016-02-11 |
Ascendis Pharma A/S |
Prodrugs comprising an aminoalkyl glycine linker
|
US10627651B2
(en)
|
2014-08-21 |
2020-04-21 |
Johnson & Johnson Vision Care, Inc. |
Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers
|
US9941547B2
(en)
|
2014-08-21 |
2018-04-10 |
Johnson & Johnson Vision Care, Inc. |
Biomedical energization elements with polymer electrolytes and cavity structures
|
US9383593B2
(en)
|
2014-08-21 |
2016-07-05 |
Johnson & Johnson Vision Care, Inc. |
Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators
|
US10381687B2
(en)
|
2014-08-21 |
2019-08-13 |
Johnson & Johnson Vision Care, Inc. |
Methods of forming biocompatible rechargable energization elements for biomedical devices
|
US10361405B2
(en)
|
2014-08-21 |
2019-07-23 |
Johnson & Johnson Vision Care, Inc. |
Biomedical energization elements with polymer electrolytes
|
US9923177B2
(en)
*
|
2014-08-21 |
2018-03-20 |
Johnson & Johnson Vision Care, Inc. |
Biocompatibility of biomedical energization elements
|
US9599842B2
(en)
|
2014-08-21 |
2017-03-21 |
Johnson & Johnson Vision Care, Inc. |
Device and methods for sealing and encapsulation for biocompatible energization elements
|
US9793536B2
(en)
|
2014-08-21 |
2017-10-17 |
Johnson & Johnson Vision Care, Inc. |
Pellet form cathode for use in a biocompatible battery
|
US10361404B2
(en)
|
2014-08-21 |
2019-07-23 |
Johnson & Johnson Vision Care, Inc. |
Anodes for use in biocompatible energization elements
|
US9715130B2
(en)
|
2014-08-21 |
2017-07-25 |
Johnson & Johnson Vision Care, Inc. |
Methods and apparatus to form separators for biocompatible energization elements for biomedical devices
|
US20160106737A1
(en)
|
2014-10-20 |
2016-04-21 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extended Release Abuse Deterrent Liquid Fill Dosage Form
|
EP3210623B1
(en)
|
2014-10-24 |
2022-10-05 |
NOF Corporation |
Antibody-drug complex having cyclic benzylidene acetal linker
|
EP3303365A4
(en)
|
2015-05-29 |
2019-04-24 |
Ascendis Pharma Inc. |
PRODRUGS WITH A PYROGLUTAMATE LINKER
|
MA42924A
(fr)
|
2015-09-23 |
2018-08-01 |
Hoffmann La Roche |
Variants optimisés d'anticorps anti-vegf
|
US11458041B2
(en)
*
|
2015-10-08 |
2022-10-04 |
Ocular Therapeutix, Inc. |
Punctal plug and bioadhesives
|
US10155063B2
(en)
|
2015-11-12 |
2018-12-18 |
University Of Virginia Patent Foundation |
Methods for vas-occlusive contraception and reversal thereof
|
US10444250B2
(en)
|
2015-12-17 |
2019-10-15 |
Janssen Pharmaceutica Nv |
Antibodies to risperidone and use thereof
|
US11285103B2
(en)
*
|
2015-12-18 |
2022-03-29 |
Jie Han |
Degradable hydrogel under physiological conditions
|
WO2017112704A1
(en)
|
2015-12-23 |
2017-06-29 |
Viking Scientific, Inc. |
Hydrogel prodrug for treatment
|
US11931480B2
(en)
|
2016-02-16 |
2024-03-19 |
The Regents Of The University Of California |
Microporous annealed particle gels and methods of use
|
US10345620B2
(en)
|
2016-02-18 |
2019-07-09 |
Johnson & Johnson Vision Care, Inc. |
Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices
|
IL301616A
(en)
|
2016-03-01 |
2023-05-01 |
Ascendis Pharma Bone Diseases As |
PTH medications
|
WO2017175200A1
(en)
|
2016-04-08 |
2017-10-12 |
The Regents Of The University Of California |
Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents
|
CN105963792B
(zh)
*
|
2016-04-29 |
2019-03-22 |
深圳迈普再生医学科技有限公司 |
医用水凝胶组合物,医用水凝胶及其制备方法与应用
|
AU2017295938C1
(en)
|
2016-07-13 |
2021-10-07 |
Ascendis Pharma A/S |
Conjugation method for carrier-linked prodrugs
|
US11564974B2
(en)
|
2016-09-29 |
2023-01-31 |
Ascendis Pharma Growth Disorders A/S |
Combination therapy with controlled-release CNP agonists
|
US20190224329A1
(en)
|
2016-09-29 |
2019-07-25 |
Ascendis Pharma Bone Diseases A/S |
Incremental Dose Finding in Controlled-Release PTH Compounds
|
DK3518961T3
(da)
|
2016-09-29 |
2023-04-24 |
Ascendis Pharma Bone Diseases As |
PTH-forbindelser med lave forhold mellem top og bund
|
PL3518960T3
(pl)
|
2016-09-29 |
2023-12-27 |
Ascendis Pharma Bone Diseases A/S |
Schemat dawkowania związku pth o kontrolowanym uwalnianiu
|
WO2018136205A1
(en)
|
2016-12-29 |
2018-07-26 |
Tempo Therapeutics, Inc. |
Methods and systems for treating a site of a medical implant
|
JP7335821B2
(ja)
|
2017-03-10 |
2023-08-30 |
ユニヴァーシティ オブ ルイビル リサーチ ファンデーション インコーポレイテッド |
免疫調節機能を有するFasL操作を受けた生体材料
|
SG10202107829YA
(en)
|
2017-03-22 |
2021-08-30 |
Genentech Inc |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
JOP20190245A1
(ar)
*
|
2017-04-20 |
2019-10-15 |
Novartis Ag |
أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
|
CN108864258A
(zh)
*
|
2017-05-12 |
2018-11-23 |
北京康明海慧生物科技有限公司 |
具有抑制肿瘤功能的peg化多肽及其制备方法与应用
|
WO2018232176A1
(en)
|
2017-06-16 |
2018-12-20 |
The University Of Chicago |
Compositions and methods for inducing immune tolerance
|
CN107583104B
(zh)
*
|
2017-10-31 |
2020-12-01 |
无锡中科光远生物材料有限公司 |
一种可注射的用于脊柱修复的凝胶材料
|
JP2021501796A
(ja)
*
|
2017-11-02 |
2021-01-21 |
タルシウス ファーマ リミテッド |
眼炎症を治療するためのホスホリルコリン−タフトシン複合体
|
CN107880288A
(zh)
*
|
2017-11-29 |
2018-04-06 |
桂林华诺威生物科技有限公司 |
一种透明质酸钠凝胶的制备方法
|
CN108096630B
(zh)
*
|
2018-01-29 |
2020-09-04 |
暨南大学 |
一种载淫羊藿苷和去铁胺的聚乳酸基骨组织支架及制备方法和应用
|
IL308797A
(en)
|
2018-03-28 |
2024-01-01 |
Ascendis Pharma Oncology Div A/S |
IL-2 conjugates
|
FR3079421A1
(fr)
*
|
2018-03-28 |
2019-10-04 |
Edix Sa |
Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide
|
CN110865130B
(zh)
*
|
2018-08-27 |
2023-08-22 |
北京海晶生物医药科技有限公司 |
一种盐酸奥洛他定及其有关物质的检测方法
|
CA3114329A1
(en)
|
2018-09-26 |
2020-04-02 |
Ascendis Pharma A/S |
Novel hydrogel conjugates
|
TW202027794A
(zh)
*
|
2018-10-03 |
2020-08-01 |
瑞士商諾華公司 |
血管生成素樣3多肽之持續遞送
|
CN111077235B
(zh)
*
|
2018-10-19 |
2023-09-08 |
重庆医药工业研究院有限责任公司 |
一种测定2-[(2-甲基-5-溴苯基)甲基]-5-(4-氟苯基)噻吩杂质的方法
|
CA3125533A1
(en)
|
2019-01-04 |
2020-07-09 |
Ascendis Pharma Oncology Division A/S |
Conjugates of pattern recognition receptor agonists
|
WO2020141225A1
(en)
|
2019-01-04 |
2020-07-09 |
Ascendis Pharma A/S |
Minimization of systemic inflammation
|
KR20210113272A
(ko)
|
2019-01-04 |
2021-09-15 |
아센디스 파마 온콜로지 디비전 에이/에스 |
선천 면역 작용제를 위한 지속되는 국소 약물 수준
|
EP3906018A1
(en)
|
2019-01-04 |
2021-11-10 |
Ascendis Pharma Oncology Division A/S |
Induction of sustained local inflammation
|
US11471497B1
(en)
|
2019-03-13 |
2022-10-18 |
David Gordon Bermudes |
Copper chelation therapeutics
|
IL295911A
(en)
*
|
2019-06-07 |
2022-10-01 |
Likarda Llc |
Targetable microparticle dissolution of hydrogels
|
WO2020254617A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pk properties
|
WO2020254606A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma A/S |
Conjugates of heteroaromatic nitrogen-comprising compounds
|
CA3143436A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma A/S |
Conjugates of .pi.-electron-pair-donating heteroaromatic nitrogen-comprising compounds
|
WO2020254613A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
|
EP3986471A1
(en)
|
2019-06-21 |
2022-04-27 |
Ascendis Pharma A/S |
Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
|
TW202114660A
(zh)
|
2019-06-21 |
2021-04-16 |
丹麥商阿仙帝斯製藥公司 |
酪胺酸激酶抑制劑結合物
|
WO2020254612A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
|
WO2020254607A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pd properties
|
US20220305136A1
(en)
|
2019-06-21 |
2022-09-29 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 conjugates
|
JP2022538868A
(ja)
*
|
2019-06-26 |
2022-09-06 |
バイオーケストラ カンパニー, リミテッド |
ミセルナノ粒子及びその使用
|
AU2020300695A1
(en)
*
|
2019-07-03 |
2022-01-27 |
Molly Sandra Shoichet |
Hydrogel compositions and uses thereof
|
CN112168820B
(zh)
*
|
2019-07-05 |
2023-09-29 |
中国科学院生物物理研究所 |
SRCAP ATPase抑制剂在结直肠癌治疗中的应用
|
WO2021042043A1
(en)
*
|
2019-08-29 |
2021-03-04 |
Paul Douglas Godfrin |
Hydrogels as oral delivery dosage forms, methods of making and using same
|
KR20220104718A
(ko)
*
|
2019-11-19 |
2022-07-26 |
루브리졸 어드밴스드 머티어리얼스, 인코포레이티드 |
비스비구아니드로 염화되는 폴리우레탄 조성물
|
EP4084872A1
(en)
|
2020-01-03 |
2022-11-09 |
Ascendis Pharma A/S |
Conjugates undergoing intramolecular rearrangements
|
CN111138293B
(zh)
*
|
2020-01-10 |
2023-07-07 |
蚌埠丰原医药科技发展有限公司 |
一种用微通道反应器合成富马酸伊布利特中间体的方法
|
ES2952213T3
(es)
|
2020-02-06 |
2023-10-30 |
Ocular Therapeutix Inc |
Composiciones y métodos para tratar enfermedades oculares
|
KR102375663B1
(ko)
*
|
2020-03-24 |
2022-03-16 |
재단법인대구경북과학기술원 |
무손실 세포 염색 방법 및 장치
|
MX2022010333A
(es)
|
2020-03-25 |
2022-12-08 |
Ocular Therapeutix Inc |
Implante ocular que contiene un inhibidor de la tirosina cinasa.
|
WO2021224169A1
(en)
|
2020-05-04 |
2021-11-11 |
Ascendis Pharma A/S |
Hydrogel irradiation
|
CN113694261B
(zh)
*
|
2020-05-21 |
2022-09-09 |
江苏百赛飞生物科技有限公司 |
一种抗菌复合涂层及其制备方法和制品
|
WO2021243309A1
(en)
*
|
2020-05-28 |
2021-12-02 |
Sollievo Pharmaceuticals, Inc |
Parenteral delivery of avizafone
|
IL298642A
(en)
|
2020-06-03 |
2023-01-01 |
Ascendis Pharma Oncology Div A/S |
il-2 sequences and uses thereof
|
US11739166B2
(en)
|
2020-07-02 |
2023-08-29 |
Davol Inc. |
Reactive polysaccharide-based hemostatic agent
|
AU2021319863A1
(en)
|
2020-08-05 |
2023-02-16 |
Ascendis Pharma A/S |
Conjugates comprising reversible linkers and uses thereof
|
CA3189715A1
(en)
|
2020-08-28 |
2022-03-03 |
Ascendis Pharma Oncology Division A/S |
Glycosylated il-2 proteins and uses thereof
|
AU2021349316A1
(en)
|
2020-09-28 |
2023-04-27 |
Ascendis Pharma Bone Diseases A/S |
Improvement of physical and mental well-being of patients with hypoparathyroidism
|
CN112316156B
(zh)
*
|
2020-10-27 |
2022-03-15 |
四川大学 |
具抗氧化和抗菌性的胶原蛋白修复膜、其制备方法及应用
|
KR102437315B1
(ko)
*
|
2020-11-02 |
2022-08-30 |
아주대학교산학협력단 |
하이브리드 하이드로겔 및 이의 생의학적 용도
|
KR20230164709A
(ko)
|
2021-04-01 |
2023-12-04 |
아센디스 파마 에이에스 |
염증 유발 질환을 치료하기 위한 지속형 성장 호르몬의 용도
|
CN113304139B
(zh)
*
|
2021-06-30 |
2022-04-29 |
贵州医科大学 |
Viniferifuran在制备黄嘌呤氧化酶抑制药物中的应用
|
CN113398145B
(zh)
*
|
2021-07-02 |
2022-10-14 |
合肥康诺生物制药有限公司 |
含nad与氨氯地平的药物组合物及其用途
|
CN113461979A
(zh)
*
|
2021-07-19 |
2021-10-01 |
吉林大学 |
一种通过血红蛋白催化交联的仿贻贝类水凝胶的制备方法
|
WO2023110727A2
(en)
|
2021-12-13 |
2023-06-22 |
Ascendis Pharma Oncology Division A/S |
Novel cancer treatments with tlr7/8 agonists
|
CN114469926B
(zh)
*
|
2022-01-28 |
2023-06-27 |
吉林省健维天然生物科技有限公司 |
二氢槲皮素的新用途及二氢槲皮素水凝胶的制备方法
|
CN115109275B
(zh)
*
|
2022-08-29 |
2022-11-01 |
杭州艾名医学科技有限公司 |
一种动态交联可降解水凝胶、制备方法及应用
|
CN115444840B
(zh)
*
|
2022-09-15 |
2023-08-25 |
四川大学 |
一种前药、两性离子水凝胶及其制备方法、应用
|
CN115322397B
(zh)
*
|
2022-09-23 |
2024-04-30 |
福州大学 |
一种预防术后腹腔粘连的两性离子水凝胶及其制备方法
|
CN115537017B
(zh)
*
|
2022-09-27 |
2023-09-01 |
四川大学 |
一种水凝胶及其制备方法和应用
|
WO2024094673A1
(en)
|
2022-11-02 |
2024-05-10 |
Ascendis Pharma Bone Diseases A/S |
Pth treatment regimen comprising two pth compounds
|